Clinical Trials

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Neoplasms

NCT06211764 2026-03-17

SunRISe-5

272 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04452591 2026-03-16

BOND-003

190 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT05316155 2026-03-13

Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer

235 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06319820 2026-03-13

MoonRISe-1

Phase 3 Recruiting

641 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06919965 2026-03-13

MoonRISe-3

Phase 3 Recruiting

220 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07309445 2026-03-13

Nova-sTAR

Recruiting

150 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT07206225 2026-03-11

A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer

Phase 1 Recruiting

294 enrolled

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07464145 2026-03-11

RESCUE

393 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Neoplasms, Urologic Neoplasms

NCT06443944 2026-03-06

An Expanded Access Program of Cretostimogene Grenadenorepvec for Treatment of NMIBC for Patients Unresponsive to BCG

Available

Phase 1/2 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07445308 2026-03-03

The Study is to Evaluate the Safety and Tolerability of SPGL008 Alone or in Combination With BCG in the Patients With NMIBC, and to Determine the RP2D of SPGL008 Alone or in Combination With BCG.To Evaluate the Preliminary Efficacy of SPGL008 Alone or in Combination With BCG.

120 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT04172675 2026-02-24

A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)

Phase 2 Completed

107 enrolled 17 charts

Phase 3 Not yet recruiting

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07424287 2026-02-20

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

236 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT05710848 2026-02-19

A Study of STM-416 Administered to Patients Undergoing TURBT for Recurrent Bladder Cancer

75 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06637423 2026-02-19

TroFuse-027

32 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06026332 2026-02-17

ABLE-41

Terminated

202 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06877676 2026-02-13

Pre-Approval Expanded Access Study for TAR-200 Treating Physician Use

Approved for marketing

Non-Muscle Invasive Bladder Neoplasms

NCT05951179 2026-01-27

ADVANCED-2

Phase 2 Recruiting

131 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04752722 2026-01-26

LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve

350 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ

NCT04165317 2026-01-22

CREST

1,068 enrolled 20 charts

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07283835 2026-01-21

Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin

Phase 2 Recruiting

16 enrolled

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT06331299 2026-01-15

UTOPIA

99 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05375903 2026-01-14

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Phase 1 Completed

51 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT06810141 2026-01-14

ResQ132EX-NMIBC: Expanded Access Use of Recombinant Bacillus Calmette-Guérin in Nonmuscle Invasive Bladder Cancer

Available

Phase 1/2 Active not recruiting

Non-Muscle Invasive Bladder Neoplasms

NCT05544552 2026-01-12

SURF301

310 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis, Urologic Neoplasms

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

367 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT07144319 2025-12-26

ENAiBLE

Not yet recruiting

500 enrolled